cephalosporin antibiotic

cephalosporin antibiotic

References in periodicals archive ?
18, 2015 /PRNewswire/ -- TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, announced the presentation of results demonstrating the synergistic antibacterial activity of its lead clinical candidate, TXA709, when combined with cefdinir, a third-generation cephalosporin antibiotic.
Currently, CDC STD treatment guidelines recommend dual therapy with a cephalosporin antibiotic - Ceftriaxone is preferred - and either azithromycin or doxycycline to treat all uncomplicated gonococcal infections among adults and adolescents in the United States.
NXL104 in combination with the cephalosporin antibiotic ceftazidime (CAZ-104) is currently in two Phase II clinical trials in patients with complicated intra-abdominal infections (cIAIs) and patients with complicated urinary tract infections (cUTIs).
Cefepime, a cephalosporin antibiotic, is approved for the treatment of a variety of infections due to its extended spectrum of activity against Gram-positive and Gram-negative bacteria.
Ceftobiprole (BAL5788), Basilea's lead antibacterial product is the first cephalosporin antibiotic with both anti-MRSA and broad-spectrum activity in late-stage clinical trials.
22] He inserted a special silicone and Merocel pack for 5 to 7 days under cephalosporin antibiotic cover following combined endoscopic paranasal sinus surgery and septoplasty.
The scientists attached a light-sensitive component to a cephalosporin antibiotic chosen to represent important characteristics of this class of drugs.
However, the Centers for Disease Control and Prevention (CDC) released new gonorrhea treatment guidelines in 2010, recommending dual therapy with a cephalosporin antibiotic and either azithromycin or doxycycline to treat most cases of infection, after reported cases of disease resistance to monotherapy spawned fears of potential gonococcal cephalosporin resistance.
S-649266 is a new parenteral siderophore cephalosporin antibiotic discovered by Shionogi & Co.
These are the injectable beta-lactamase inhibitor, NXL104, which is being developed in combination with the cephalosporin antibiotic ceftazidime for serious Gram negative infections, and the oral streptogramin antibiotic, NXL103, for the treatment of Gram positive infections, with a focus on treatment in the hospital setting and intravenous (IV) to oral switch.
Currently the pipeline comprises third-generation cephalosporin antibiotic, Cephalosporin + Tetracycline combinations, Lyme Borreliosis vaccines, OspA vaccine and OspA + DbpA combination vaccine
PARIS, March 3 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced injectable antibacterial, which combines Novexel's broad spectrum beta lactamase inhibitor, NXL104, with the well established cephalosporin antibiotic, ceftazidime, has entered a second Phase II clinical trial.